Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.
The narrow 50-46 decision underscored the divisions on both sides of the aisle over agency policies on opioids and abortion medications and his ties to […]
Dr. Robert Califf, a former agency commissioner, is encountering opposition over federal opioid and abortion policies and his industry ties.
Dr. Robert Califf, a former agency commissioner, is encountering opposition over federal opioid and abortion policies and his industry ties.
A split committee vote revealed concerns about the opioid epidemic and abortion policies, foreshadowing a likely close vote on confirmation by the full Senate.
A split committee vote revealed concerns about the opioid epidemic and abortion policies, foreshadowing a likely close vote on confirmation by the full Senate.
A key committee was split mainly on party lines over the nomination of Dr. Robert Califf, foreshadowing divisions in the full Senate for a vote […]
A Senate panel hearing on Tuesday signaled that Dr. Robert Califf, who briefly led the agency during the Obama administration, had some bipartisan support.
A Senate panel hearing on Tuesday signaled that Dr. Robert Califf, who briefly led the agency during the Obama administration, had some bipartisan support.
A Senate panel hearing on Tuesday signaled that Dr. Robert Califf, who briefly led the agency during the Obama administration, had some bipartisan support.
A Senate panel hearing on Tuesday signaled that Dr. Robert Califf, who briefly led the agency during the Obama administration, had some bipartisan support.
The 135-year-old company announced plans to divide itself into a consumer products business and a medical company.
Dr. Robert M. Califf, an academic and clinical trial researcher who ran the agency in 2016, has also consulted for pharmaceutical companies.
Dr. Robert M. Califf, an academic and clinical trial researcher who ran the agency in 2016, has also consulted for pharmaceutical companies.
Dr. Robert M. Califf, an academic and clinical trial researcher who ran the agency in 2016, has also consulted for pharmaceutical companies.
Dr. Robert M. Califf, an academic and clinical trial researcher who ran the agency in 2016, has also consulted for pharmaceutical companies.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
President Biden should choose the next director of the U.S. Patent and Trademark Office carefully.
President Biden should choose the next director of the U.S. Patent and Trademark Office carefully.
President Biden should choose the next director of the U.S. Patent and Trademark Office carefully.
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official for the initiative […]
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official for the initiative […]
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official for the initiative […]
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official for the initiative […]
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official for the initiative […]
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official for the initiative […]
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official at Operation Warp […]
Copyright © 2024 | WordPress Theme by MH Themes